Oracle Runs

Will the results be positive?

Trial NCT06522997 (ALPINE-1, BAY3283142 Phase 2 CKD) is active not recruiting, with estimated primary completion 2026-02-12. No public results, readouts, or topline data found across web searches, Bayer pipeline (ongoing as of Feb 2026), or ClinicalTrials.gov (no results posted, last update Nov 2025). Ongoing status precludes positive/negative classification.

Will the results be positive?

Trial is ongoing (active, not recruiting; primary completion Feb 2026). No public results, topline, or readout found. All sources are pre-results (initiation announcements, protocol). No evidence of positive or negative framing for this exact Phase 2 trial.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific efficacy readout was found. The best current public evidence indicates ALPINE-1/NCT06522997 is still listed as ongoing by Bayer, and an independent FDAAA tracker shows no actual results reporting yet. That is insufficient to call the Phase 2 readout positive or negative.

Will the results be positive?

No trial-specific public efficacy readout was located. Bayer’s own February 11, 2026 pipeline still lists NCT06522997 / ALPINE-1 as “Study ongoing,” and Bayer’s January 2026 JPM materials frame ALPINE-1 topline as an expected Q1 2026 milestone rather than a reported result. That is insufficient to call the trial positive or negative.